Compounds > sorafenib
Page last updated: 2024-09-05

sorafenib and arsenic trioxide

sorafenib has been researched along with arsenic trioxide in 8 studies

Compound Research Comparison

Studies
(sorafenib)		Trials
(sorafenib)		Recent Studies (post-2010)
(sorafenib)		Studies
(arsenic trioxide)		Trials
(arsenic trioxide)		Recent Studies (post-2010) (arsenic trioxide)
6,5207305,2513,1191601,507
6,5207305,251505
6,5207305,251704

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (12.50)29.6817
2010's6 (75.00)24.3611
2020's1 (12.50)2.80

Authors

AuthorsStudies
Cui, YZ; Luo, RC; Wu, J; Zhang, H1
Bechelli, J; Ifthikharuddin, JJ; Jordan, CT; Liesveld, JL; Lu, C; Messina, P; Mulford, D; Phillips Ii, GL; Rosell, KE1
Allensworth, JL; Devi, GR; Diehl, AM; Lyerly, HK; Morse, MA; Rangwala, F; Smith, GR; Thomas, Z; Williams, KP1
He, C; Jiang, H; Jiang, X; Ma, L; Sun, X; Xu, L; Zhai, B; Zhao, D1
Chen, C; Hu, H; Li, H1
Gabrilove, J; Gong, P; Jing, Y; Li, Y; Wang, R; Waxman, S1
Chen, D; Chen, L; Fan, T; Gao, Z; Jiang, Y; Li, Y; Liu, Z; Qiu, Z; Wai Wong, VK; Wu, W; Yang, M; Zhang, C; Zhou, Y1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1

Reviews

1 review(s) available for sorafenib and arsenic trioxide

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Trials

1 trial(s) available for sorafenib and arsenic trioxide

ArticleYear
Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines.
    Cancer investigation, 2011, Volume: 29, Issue:7

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Azacitidine; Benzenesulfonates; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cytarabine; Cytokines; Farnesyltranstransferase; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Niacinamide; Oxides; Phenylurea Compounds; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyridines; Sorafenib

2011

Other Studies

6 other study(ies) available for sorafenib and arsenic trioxide

ArticleYear
[Inhibitory effect of sorafenib combined with arsenic trioxide on hepatocellular carcinoma cells].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2008, Volume: 28, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzenesulfonates; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Humans; Liver Neoplasms; Membrane Potential, Mitochondrial; Niacinamide; Oxides; Phenylurea Compounds; Pyridines; Sorafenib

2008
Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines.
    BMC cancer, 2012, Sep-10, Volume: 12

    Topics: Adult; AMP-Activated Protein Kinases; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blotting, Western; Carcinoma, Hepatocellular; Cell Line; Cell Proliferation; Cell Survival; Drug Synergism; Enzyme Activation; Fluorouracil; Gene Expression Regulation, Enzymologic; Growth Inhibitors; Hep G2 Cells; Hepatic Stellate Cells; Humans; Inhibitory Concentration 50; Liver Neoplasms; Niacinamide; Oxides; Phenylurea Compounds; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Thymidylate Synthase; Time Factors

2012
Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015, Volume: 36, Issue:4

    Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Proliferation; Drug Synergism; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Neoplasm Proteins; Niacinamide; Oxides; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib

2015
[Treatment of refractory pulmonary metastases from hepatocellular carcinoma by transcatheter arterial chemoembolization using arsenic trioxide in combination with sorafinib].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2015, Volume: 37, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Lung Neoplasms; Niacinamide; Oxides; Phenylurea Compounds; Sorafenib

2015
Arsenic Trioxide and Sorafenib Induce Synthetic Lethality of FLT3-ITD Acute Myeloid Leukemia Cells.
    Molecular cancer therapeutics, 2018, Volume: 17, Issue:9

    Topics: Acute Disease; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Cell Line, Tumor; fms-Like Tyrosine Kinase 3; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Sorafenib; Synthetic Lethal Mutations; Tandem Repeat Sequences; THP-1 Cells; Xenograft Model Antitumor Assays

2018
Design, synthesis and antitumor evaluation of novel 1H-indole-2-carboxylic acid derivatives targeting 14-3-3η protein.
    European journal of medicinal chemistry, 2022, Aug-05, Volume: 238

    Topics: 14-3-3 Proteins; Antineoplastic Agents; Apoptosis; Carboxylic Acids; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; Indoles; Liver Neoplasms; Molecular Docking Simulation; Structure-Activity Relationship

2022